Serious traumatic injuries to the skeleton that result in unrepairable destruction of structural bone must be treated with either a limb salvage procedure that replaces the bone segment, or amputation. As limb salvage is the favorable outcome, the absence of a highly efficacious approach to replace the bone segment that will osteointegrate and restore normal function indefinitely remains a significant problem. Since human cortical bone is the ideal replacement material to fill segmental defects, structural allografts have been used for over 50 years for this purpose. Unfortunately, the absence of a vascular supply, and limited bone forming and remodeling of structural allografts is directly associated with the 25% to 35% failure rate within 3-years due to infection, fracture and nonunion. For those that survive, the failure rate at 10-years has been documented to be as high as 60%. As a result of this poor clinical success, the use of structural allografts has been restricted to repair segmental defects following tumor resection in cancer patients. Furthermore, since traumatic wounds are often contaminated with compromised soft tissue coverage, and necrotic bone is a nitrous for infection, the use of structural allografts to repair these injuries is contraindicated. To the end of a revitalizing structural allograft that has a vascular supply for immunity against infection and the ability to remodel microcracks, we have developed a revolutionary approach that introduces angiogenic, osteoclastogenic and osteogenic signals on the cortical surface via immobilized recombinant adenoassociate virus (rAAV). Based on our remarkable success with this approach in a murine femoral allograft model, here we propose to maximize its ability to reproducibly achieve unions with ideal biomechanical properties, and develop a minimally invasive outcome measure to prove its angiogenic and osteogenic properties in humans.
In Aim 1 we will determine if our remodeling allograft coated with rAAV-VEGF + rAAV-RANKL is superior to our osteogenic allograft coated with rAAV-caAlk2, and if these vectors can be efficiently combined.
In Aim 2 we will determine if PTH can be use as an adjuvant to increase bone formation and connectivity of our revitalizing allografts.
In Aim 3 we will perform a clinical pilot in auto and allograft patients to evaluate a novel vascular cone beam CT outcome measure to quantify vascular and bone volume longitudinally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center (P50)
Project #
5P50AR054041-05
Application #
8116664
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$218,267
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Yukata, Kiminori; Xie, Chao; Li, Tian-Fang et al. (2018) Teriparatide (human PTH1-34) compensates for impaired fracture healing in COX-2 deficient mice. Bone 110:150-159
Zingman, Alissa; Li, Hiayan; Sundem, Leigh et al. (2017) Shoulder arthritis secondary to rotator cuff tear: A reproducible murine model and histopathologic scoring system. J Orthop Res 35:506-514
Li, Xing; Sun, Wen; Li, Jinbo et al. (2017) Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid. Sci Rep 7:41358
Schwarz, Edward M (2017) Confirmation of Sexual Dimorphisms in Metal Hypersensitivity and Joint Pain Following Total Joint Arthroplasty: Commentary on an article by Marco S. Caicedo, PhD, et al.: ""Females with Unexplained Joint Pain Following Total Joint Arthroplasty Exhibit a H J Bone Joint Surg Am 99:e41
Zhang, Longze; Wang, Tao; Chang, Martin et al. (2017) Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model. J Bone Miner Res 32:1870-1883
Feigenson, Marina; Eliseev, Roman A; Jonason, Jennifer H et al. (2017) PGE2 Receptor Subtype 1 (EP1) Regulates Mesenchymal Stromal Cell Osteogenic Differentiation by Modulating Cellular Energy Metabolism. J Cell Biochem 118:4383-4393
Wang, Wensheng; Wang, Hua; Zhou, Xichao et al. (2017) Lymphatic Endothelial Cells Produce M-CSF, Causing Massive Bone Loss in Mice. J Bone Miner Res 32:939-950
Sun, Wen; Zhang, Hengwei; Wang, Hua et al. (2017) Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis. J Bone Miner Res 32:1469-1480
Le Bleu, Heather K; Kamal, Fadia A; Kelly, Meghan et al. (2017) Extraction of high-quality RNA from human articular cartilage. Anal Biochem 518:134-138
Nishitani, Kohei; Mietus, Zachary; Beck, Christopher A et al. (2017) High dose teriparatide (rPTH1-34) therapy increases callus volume and enhances radiographic healing at 8-weeks in a massive canine femoral allograft model. PLoS One 12:e0185446

Showing the most recent 10 out of 133 publications